Iressa Follow-up Trial

Multicenter Open-label, Long-term Safety Trial of Treatment Extension With ZD1839 in Patients Who Have Been Treated in Other ZD1839 Clinical Trials.

The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).

Inclusion Criteria:

• Provision of written informed consent to participate in the trial.
• Female or male aged 18 years and over.
• Patients with previously diagnosed cancer who have been treated with ZD1839 in a parent ZD1839 clinical trial and may benefit from continuation

Exclusion Criteria:

• Known severe hypersensitivity to ZD1839
• Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.
• Withdrawal from a parent ZD1839 trial because of tumor progress